In the past week, UTHR stock has gone up by 7.36%, with a monthly gain of 4.61% and a quarterly surge of 25.48%. The volatility ratio for the week is 3.51%, and the volatility levels for the last 30 days are 3.21% for United Therapeutics Corp. The simple moving average for the past 20 days is 4.80% for UTHR’s stock, with a 34.33% simple moving average for the past 200 days.
Is It Worth Investing in United Therapeutics Corp (NASDAQ: UTHR) Right Now?
United Therapeutics Corp (NASDAQ: UTHR) has a higher price-to-earnings ratio of 15.94x compared to its average ratio, The 36-month beta value for UTHR is at 0.56. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 2 rating it as “overweight,” 6 as “hold,” and 4 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for UTHR is 43.71M, and currently, shorts hold a 9.42% of that float. The average trading volume for UTHR on August 23, 2024 was 563.20K shares.
UTHR) stock’s latest price update
The stock price of United Therapeutics Corp (NASDAQ: UTHR) has dropped by -1.35 compared to previous close of 351.61. Despite this, the company has seen a gain of 7.36% in its stock price over the last five trading days. seekingalpha.com reported 2024-08-19 that United Therapeutics Corporation remains a buy with strong growth potential and high returns on invested capital. Q2 FY’24 earnings show continued growth in sales and earnings, with upsides in its Tyvaso segment. The company has started share buybacks and is on track to reach a $3 billion revenue run rate by FY’25, supporting a valuation of $400/share.
Analysts’ Opinion of UTHR
Many brokerage firms have already submitted their reports for UTHR stocks, with Morgan Stanley repeating the rating for UTHR by listing it as a “Equal-Weight.” The predicted price for UTHR in the upcoming period, according to Morgan Stanley is $321 based on the research report published on July 11, 2024 of the current year 2024.
Goldman, on the other hand, stated in their research note that they expect to see UTHR reach a price target of $215, previously predicting the price at $213. The rating they have provided for UTHR stocks is “Neutral” according to the report published on February 12th, 2024.
Leerink Partners gave a rating of “Outperform” to UTHR, setting the target price at $330 in the report published on February 05th of the current year.
UTHR Trading at 7.76% from the 50-Day Moving Average
After a stumble in the market that brought UTHR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -1.87% of loss for the given period.
Volatility was left at 3.21%, however, over the last 30 days, the volatility rate increased by 3.51%, as shares surge +3.12% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +25.79% upper at present.
During the last 5 trading sessions, UTHR rose by +7.36%, which changed the moving average for the period of 200-days by +54.56% in comparison to the 20-day moving average, which settled at $331.51. In addition, United Therapeutics Corp saw 57.75% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at UTHR starting from ROTHBLATT MARTINE A, who sale 3,600 shares at the price of $350.14 back on Aug 21 ’24. After this action, ROTHBLATT MARTINE A now owns 130 shares of United Therapeutics Corp, valued at $1,260,496 using the latest closing price.
ROTHBLATT MARTINE A, the Chairperson & CEO of United Therapeutics Corp, sale 3,600 shares at $346.03 during a trade that took place back on Aug 20 ’24, which means that ROTHBLATT MARTINE A is holding 130 shares at $1,245,698 based on the most recent closing price.
Stock Fundamentals for UTHR
Current profitability levels for the company are sitting at:
- 0.48 for the present operating margin
- 0.89 for the gross margin
The net margin for United Therapeutics Corp stands at 0.41. The total capital return value is set at 0.21. Equity return is now at value 19.25, with 15.96 for asset returns.
Based on United Therapeutics Corp (UTHR), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at 2.21. The debt to equity ratio resting at 0.09. The interest coverage ratio of the stock is 38.99.
Currently, EBITDA for the company is 1.39 billion with net debt to EBITDA at -0.59. When we switch over and look at the enterprise to sales, we see a ratio of 5.57. The receivables turnover for the company is 9.0for trailing twelve months and the total asset turnover is 0.39. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.35.
Conclusion
In conclusion, United Therapeutics Corp (UTHR) has had a better performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
